Skip to main content

Day: July 5, 2023

Infant Formula Market to Surpass 78273.3 Million by 2030 Drives Due to the High Nutritional Value Offered by Infant Formula Products

SkyQuest projects that the infant formula market will attain a USD 78273.3 million value by 2030, with a CAGR of 10.6% over the forecast period (2023-2030). The distribution of infant formula through supermarkets is expected to witness significant growth in the infant formula market share, with a projected CAGR of over 10% through 2032. Westford, USA, July 05, 2023 (GLOBE NEWSWIRE) — According to SkyQuest, the infant formula market is poised for significant growth, primarily driven by the high nutritional value offered by infant formula products. The infant formula segment holds the largest market share within the global baby infant formula market. While breastfeeding is widely recognized as the ideal source of infant nutrition, it may not always be feasible for mothers who work outside the home or face other challenges. Get a...

Continue reading

Genco Shipping & Trading Limited Announces Second Quarter 2023 Conference Call and Webcast

NEW YORK, July 05, 2023 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE: GNK) announced today that it will hold a conference call to discuss the Company’s results for the second quarter of 2023 on Friday, August 4, 2023 at 10:00 a.m. Eastern Time. The conference call will also be broadcast live over the Internet and include a slide presentation. The Company will issue financial results for the second quarter ended June 30, 2023 on Friday, August 4, 2023 before the open of market trading.What:   Second Quarter 2023 Conference Call     When:   Friday, August 4, 2023 at 10:00 a.m. Eastern Time     Where:   There are two ways to access the call:     Dial-in:   416-764-8624 or 888-259-6580Please dial in at least 10 minutes prior to 10:00 a.m. Eastern Time to ensure a prompt start to the call. For...

Continue reading

US Nuclear Corp. Announces First Quarter 2023 Results

LOS ANGELES, CA, July 05, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — US Nuclear Corp. (OTC-QB: UCLE), a leading manufacturer of advanced radiation, chemical, and biological detection and UAV instrumentation, recently announced the financial results for the first quarter ended March 31, 2023.Sales for the three months ended March 31, 2023 were $647,706 compared to $339,515 for the same period in 2022, an increase of 47.58% Gross profit was $435,589 compared to $227,277 for the same period in 2022, an increase of 49.45% Gross margins were 67.2% as compared to 66.9% for the same period last year Selling, general, and administrative expense were $735,825 compared to $873,503 for the same period last year, the decrease of $137,678 or 18.71% was due to careful management of expenses and overhead Other expense was $364,298, an...

Continue reading

SUPERIOR GROUP OF COMPANIES ANNOUNCES THE PASSING OF GERALD (JERRY) BENSTOCK, CHAIRMAN EMERITUS OF THE BOARD OF DIRECTORS

ST. PETERSBURG, Fla., July 05, 2023 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC) today announced that Gerald (Jerry) Benstock, Chairman Emeritus of the Board of Directors, passed away on June 30, 2023 at the age of 93.   Mr. Benstock joined SGC in 1951 as an industrial engineer after graduating from night school at New York University. At a very young age, he took over the reins of the business from his father, who had suffered from severe health issues. Mr. Benstock ultimately served for decades as our CEO and Chairman, retiring as CEO in 2003 and as Chairman in 2012, whereupon he became Chairman Emeritus. Over the years, Mr. Benstock’s unwavering dedication, guidance, and transformative leadership drove much of our growth and success. We would not have achieved more than $536 million in revenue in 2022 if...

Continue reading

Brera Holdings Enters Into Definitive Agreement to Acquire Majority Stake in Italian First-Division Women’s Professional Volleyball Team Uyba Volley

North Milan-Based UYBA Volleyball Team is Led by World Championship Coach Julio Velasco and Includes Lease for E-Work Arena in Busto ArsizioBrera Director Chris Gardner and UYBA President Giuseppe Pirola at the E-Work Arena Brera Director Chris Gardner and UYBA President Giuseppe Pirola at the E-Work ArenaDUBLIN and MILAN, July 05, 2023 (GLOBE NEWSWIRE) — Brera Holdings PLC (“Brera Holdings,” “Brera” or the “Company”) (Nasdaq: BREA) today announced that it has executed the definitive agreements related to the acquisition of a majority ownership stake in the Italian Serie A1 women’s professional volleyball team UYBA Volley S.s.d.a.r.l., based in Busto Arsizio, north of Milan (“UYBA” or “UYBA Volley”). The closing of the acquisition is subject to customary closing conditions contained in the definitive agreements. “We are delighted...

Continue reading

Ormat Technologies’ Arrowleaf Solar and Storage Facility Secures Long-Term PPA with San Diego Community Power

RENO, Nev., July 05, 2023 (GLOBE NEWSWIRE) — Ormat Technologies, Inc (NYSE: ORA) and San Diego Community Power (SDCP) today announced the signing of an agreement that will bring clean, renewable, and affordable energy to the nearly 1 million customers of SDCP. Ormat, a leading renewable energy company, and SDCP, California’s second largest community choice aggregator, signed a power purchase agreement for the Arrowleaf Solar and Storage Facility demonstrating their collective commitments to delivering clean and reliable energy solutions. “We are excited to partner with San Diego Community Power on the Arrowleaf Solar and Storage Facility,” said Doron Blachar, CEO of Ormat Technologies. “This agreement represents a great outcome for SDCP and Ormat and will bring significant value from a solar plus storage facility that will strategically...

Continue reading

Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration

HAMILTON, BERMUDA , July 05, 2023 (GLOBE NEWSWIRE) — Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform in the regeneration of damaged heart tissue Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has entered into a collaboration and option agreement with Heqet Therapeutics s.r.l. (“Heqet”) utilizing the Company’s proprietary OligoPhoreTM delivery platform. Based in Turin, Italy, Heqet is a biotech spin-out from King’s College London. It is developing groundbreaking genetic medicines to reverse the damage of ischemic heart disease. Under the terms of the agreement, Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform and...

Continue reading

Inter&Co Announces New Senior Management Structure

BELO HORIZONTE, Brazil, July 05, 2023 (GLOBE NEWSWIRE) — Inter&Co, Inc (NASDAQ: INTR | B3: INBR32), the premier Super App in the Americas that provides financial and digital commerce services to more than 26 million customers, announces today a new senior management structure that will enable the Company to be better prepared to continue succeeding in the future. João Vitor Menin, Inter’s CEO, stated: “With a leaner and faster new management structure, we are clearly focused on enhancing our customer-centric approach in a cost-efficient and data-heavy manner. At the same time, the structure enables Inter to benefit both from the passion and vision of the executives who skillfully led Inter to the present, together with the fresh views and valuable experience of the new talent. I couldn’t be more excited about what’s...

Continue reading

Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study

Topline data expected in Q3 2023 Carlsbad, CA, July 05, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the completion of patient enrollment in its dose optimization study of LB1148. “Achieving our enrollment target in this study is an important milestone for our LB1148 clinical program,” commented J.D. Finley, Chief Executive Officer of Palisade Bio. “Importantly, we remain on track for the Phase 2 topline data readout for the prevention of post-surgical abdominal adhesions in the coming weeks. The data from these two studies will provide meaningful information related to our future clinical development of LB1148.” The dose optimization study was designed to generate valuable pharmacokinetic...

Continue reading

GRI Bio, Inc. (NASDAQ: GRI) to Participate in the Virtual Investor Summer Spotlight Series

– Live moderated webcast with members of the GRI Bio, Inc. management team on Tuesday, July 11th at 2:00 PM ET LA JOLLA, CA, July 05, 2023 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, Ph.D., President and Chief Executive Officer, Albert Agro, Ph.D., Chief Medical Officer and Vipin Kumar, Ph.D., Chief Scientific Officer of GRI Bio will participate in the Virtual Investor Summer Spotlight Series on Tuesday, July 11, 2023 at 2:00 PM ET. A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.gribio.com). A webcast replay...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.